FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: the use of aclidinium for preparing a medicine for treating or preventing a respiratory disease or condition in a patient by inhalation, wherein said patients showed no systemic antimuscarinic actions, where the patient suffers a condition or is susceptible thereto, which may be exacerbated by systemic antimuscarinic activity (versions), and a related method of treating or preventing.
EFFECT: invention provides local therapeutic action of aclidinium in lungs and has no significant systemic antimuscarinic action as it quickly hydrolysed in blood plasma, and its main metabolites are completely deprived of affinity to muscarinic receptors.
13 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION (VERSIONS) AND PHARMACEUTICAL PREPARATION FOR TREATING UPPER RESPIRATORY TRACT DISEASES | 2005 |
|
RU2440813C2 |
| NEW DOSE AND FORMULATION | 2009 |
|
RU2608713C2 |
| COMBINATION AND PHARMACEUTICAL PREPARATION FOR TREATMENT OF INFLAMMATORY DISEASES | 2006 |
|
RU2465915C2 |
| COMBINATIONS CONTAINING ANTIMUSCARINE AGENTS AND CORTICOSTEROIDS | 2005 |
|
RU2385721C2 |
| COMBINATIONS CONTAINING ANTIMUSCARINE AGENTS AND CORTICOSTEROIDS | 2005 |
|
RU2385156C2 |
| COMBINATIONS CONTAINING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2404771C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2642624C2 |
| COMBINATIONS CONTAINING ANTI-MUSCARINE PREPARATIONS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2379033C2 |
| PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2568882C2 |
| COMBINATIONS, CONNECTING ANTI-MUSCARINIC PREPARATIONS AND BETA-ADRENERTIC AGONISTS | 2010 |
|
RU2465902C2 |
